Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

http://hdl.handle.net/2027/mdp.39015072932885

CUMULATIVE SUPPLEMENT 4

AUG'83 - DEC'83



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
NATIONAL CENTER FOR DRUGS AND BIOLOGICS

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition, (the List) to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the List to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLT> (DELETE) to the left of the line containing the overstruck print. The >DLT> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (◆) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACETIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

Former Applicant (Name)	New Applicant (Name)	New Abbreviated Name
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	OPTOPICS LABS

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the List; (2) products that are being removed from the List as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multisource or single source during each month within the quarter. The report does not reflect category changes from multisource to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multisource and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

CATEGORIES COUNTED	JULY '83 (BASELINE)	OCT '83
DRUG PRODUCTS LISTED	6679	6783
SINGLE SOURCE	1908 (28.6%)	1915 (28.2%)
MULTISOURCE(1)	4771 (71.4%)	4868 (71.8%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)
EXCEPTIONS(2)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2
NUMBER OF APPLICANTS	304	310

B. ACTIVITY FOR SUPPLEMENT NUMBER 4

	NOV '83	DEC '83	CUMULATIVE
DRUG PRODUCTS ADDED:	43	39	82
NEWLY APPROVED	43	39	82
DESI EFFECTIVE	0	0	0
REMARKETED	0	0	0
DRUG PRODUCTS REMOVED:	36	6	42
WITHDRAWN APPROVAL	27	0	27
RX TO OTC SWITCH	0	0	0
DISCONTINUED MARKETING	9	6	15
NET GAIN IN DRUG PRODUCTS	7	33	40
SINGLE SOURCE PRODUCTS APPROVED	10	9	19
MULTISOURCE DRUG PRODUCTS APPROVED	33	30	63
NEW MOLECULAR ENTITIES APPROVED:	3	2	5
AS THE ENTITY	3	1	4
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	0	1	1

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (i.e., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE I-5 OF THE LIST)

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL
> ADD > ACETAMINOPHEN W/ CODEINE #3
> ADD > AA LEMMON 300MG;30MG*
TYLENOL W/ CODEINE NO. 3
> ADD > AA MCNEIL PHARM 300MG;30MG

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL
> ADD > CODACET
> ADD > AA HALSEY DRUG 325MG;5MG*
/PERCOCET-5/
PERCOCET

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOLAMINE HYDROCHLORIDE; PHENYLTOLOXAMINE CITRATE/ (PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
/RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 131/
/MALLINCKRODT/ /6.7-250 UCI/ML/

AMINOPHYLLINE (PAGE 3-8)

/LIQUID; ORAL/
SOLUTION; ORAL
AMINOPHYLLINE
> ADD > AA BAY LABORATORIES 105MG/5ML*
AA ROXANE LABORATORIES 105MG/5ML*

TABLET; ORAL
AMINOPHYLLINE
BD BARR LABORATORIES 100MG*
BD 200MG*
AB VANGARD LABS/MWM 100MG*
AB 200MG*

/AMPHETAMINE SULFATE/ (PAGE 3-13)

/CAPSULE; CONTROLLED RELEASE; ORAL
/BENZEDRINE/
/SKF LABORATORIES/ /15MG/

/AMPHETAMINE SULFATE/ (PAGE 3-13)

/TABLET; ORAL/
/BENZEDRINE/
/SKF LABORATORIES/ /5MG/
/10MG/

AMPICILLIN TRIHYDRATE; PROBENECID (PAGE 3-13)

POWDER FOR RECONSTITUTION; ORAL
POLYCILLIN-PRB
AB BRISTOL LABS/B-M EQ 3.5GM BASE/BOT;1GM/BOT
PROBAMPACIN
AB BIOCRAFT LABS EQ 3.5GM BASE/BOT;1GM/BOT

ASPIRIN; BUTALBITAL (PAGE 3-15)

TABLET; ORAL
AXOTAL
ADRIA LABORATORIES 650MG;50MG*

ASPIRIN; BUTALBITAL; CAFFEINE (PAGE 3-15)

TABLET; ORAL
ASPIRIN AND CAFFEINE W/ BUTALBITAL
PUREPAC/KALIPHARMA 325MG;50MG;40MG*

/ASPIRIN; BUTALBITAL; CAFFEINE; PHENACETIN/ (PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE (PAGE 3-15)

CAPSULE; ORAL
SYNALGOS-DC
IVES LABS/AMHO 356.4MG;30MG;16MG*

/ASPIRIN; CAFFEINE; PHENACETIN; PROPOXYPHENE HYDROCHLORIDE/ (PAGE 3-15)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
DARVON COMPOUND-65
AA ELI LILLY INDSTRS/PR 389MG;32.4MG;65MG

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE (PAGE 3-16)

CAPSULE; ORAL
PROPOXYPHENE COMPOUND 65
AA LEMMON 389MG;32.4MG;65MG*
SK-65 COMPOUND
AA SK&F LABORATORIES 389MG;32.4MG;65MG*

ASPIRIN; CARISOPRODOL (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND
WALLACE PHARMS/C-W 325MG;200MG*

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE (PAGE 3-16)

TABLET; ORAL
SOMA COMPOUND W/ CODEINE
WALLACE PHARMS/C-W 325MG;200MG;16MG*

ASPIRIN; HYDROCODONE BITARTRATE (PAGE 3-16)

TABLET; ORAL
VICOPRIN
KNOLL PHARMACEUTICAL 500MG;5MG*

ATRACURIUM BESYLATE (PAGE 3-16)

INJECTABLE; INJECTION
TRACRIUM
BURROUGHS WELLCOME 10MG/ML*

/AZURESIN/(PAGE 3-18)

/GRANULE; ORAL/
/DIAGNEX BLUE/
/E.R. SQUIBB AND SONS/ /2GM/PACKET/

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
PFIZER LABS/PFIZER 800MG*

> ADD > BENTIROMIDE (PAGE 3-19)

> ADD > SOLUTION; ORAL
> ADD > CHYMEX
> ADD > ADRIA LABORATORIES 500MG/7.5ML*

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
/PROAQUA/
/BP/ /REID-PROVIDENT LABS//50MG/

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*

LOTION; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL
BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASE*
AB PHARMADERM/BYK-GLDN EQ 0.1% BASE*
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASE*
VALISONE
AB SCHERING EQ 0.1% BASE

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL
BROMPHENIRAMINE MALEATE
/AA/ /BOLAR PHARMACEUTICAL/4MG/

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION
MARCAINE HCL W/ EPINEPHRINE
AP BREON LABS/STERLING 0.5%;0.0091MG/ML
AP 0.75%;0.0091MG/ML
SENSORCAINE
AP ASTRA HOSP PHARM 0.5%;0.0091MG/ML*
AP 0.75%;0.0091MG/ML*

BUTABARBITAL SODIUM (PAGE 3-24)

ELIXIR; ORAL

	BUTABARBITAL SODIUM		
AA	WEST-WARD		33MG/5ML
	BUTALAN		
AA	LANNETT	33.3MG/5ML	

CAFFEINE; CARISOPRODOL; CODEINE PHOSPHATE; PHENACETIN (PAGE 3-24)

TABLET; ORAL

	SOMA COMPOUND W/ CODEINE		
	WALLACE PHARMS/C-W	32MG;200MG;16MG;160MG	

CAFFEINE; CARISOPRODOL; PHENACETIN (PAGE 3-25)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL

	CAFERGOT	
BR	SANDOZ PHARMS/SANDOZ	100MG;2MG
	WIGRAINE	
BR	ORGANON/AKZONA	100MG;2MG*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL

	DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER	
	AM MCGAW/AM HOSP	510MG/100ML;30GM/100ML; 200MG/100ML;9.2GM/100ML; 9.6GM/100ML*
		510MG/100ML;30GM/100ML; 200MG/100ML;9.4GM/100ML; 11GM/100ML*
	DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER	
	AM MCGAW/AM HOSP	510MG/100ML;50GM/100ML 200MG/100ML;9.2GM/100ML; 9.6GM/100ML*
		510MG/100ML;50GM/100ML; 200MG/100ML;9.4GM/100ML; 11GM/100ML*

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL

	DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER	
	AM MCGAW/AM HOSP	26MG/100ML;2.5GM/100ML; 15MG/100ML;560MG/100ML;390MG/100ML*

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE (PAGE 3-27)

INJECTABLE; INJECTION

	ISOLYTE E IN PLASTIC CONTAINER	
	AM MCGAW/AM HOSP	35MG/100ML;30MG/100ML; 74MG/100ML;640MG/100ML; 500MG/100ML;74MG/100ML*

CEFTIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION

	CEFIZOX	
	SK&F LABORATORIES	EQ 1GM BASE/VIAL*
		EQ 2GM BASE/VIAL*

CEFUROXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION

	ZINACEF	
	GLAXO	EQ 750MG BASE/VIAL*
		EQ 1.5GM BASE/VIAL*

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION

	KEFLIN	
AP	ELI LILLY	EQ 1GM BASE/VIAL
AP		EQ 2GM BASE/VIAL
	SEFFIN	
AP	GLAXO	EQ 1GM BASE/VIAL*
AP		EQ 2GM BASE/VIAL*
		EQ 10GM BASE/VIAL*

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL

	LIBRELEASE	
	HOFFMANN-LA ROCHE	30MG*

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /BOOTS PHARMACEUTICAL/ 5MG/
/AB/ 10MG/
/AB/ 25MG/

CHLOROTHIAZIDE (PAGE 3-35)

TABLET; ORAL
CHLOROTHIAZIDE
AB CHELSEA LABORATORIES 250MG*
AB 500MG*

CHLOROTHIAZIDE; RESERPINE (PAGE 3-35)

TABLET; ORAL
>ADD> CHLOROTHIAZIDE AND RESERPINE
>ADD> BP WEST-WARD 250MG;0.125MG*
>ADD> BP 500MG;0.125MG*

CHLORPHENIRAMINE MALEATE (PAGE 3-36)

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /TOWNE,PAULSEN/ /4MG/

CHLORTHALIDONE (PAGE 3-38)

TABLET; ORAL
CHLORTHALIDONE
AB PUREPAC/KALIPHARMA 50MG*

CHLORZOXAZONE (PAGE 3-39)

TABLET; ORAL
CHLORZOXAZONE
AA PAR PHARMACEUTICAL 250MG*

CIMETIDINE (PAGE 3-39)

TABLET; ORAL
TAGAMET
>ADD> SK&F LAB 400MG*

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
/REPOSITORY CORTICOTROPIN/
/BC/ /WYETH LABS/AMHO/ /40 UNITS/ML/
/BC/ /80 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
DODECAMIN
AP MAURRY BIOLOGICAL 1MG/ML*
REDISOL
/AP/ MS&D/MERCK /0.1MG/ML/
SYTOBEX
/AP/ PARKE DAVIS/W-L /0.1MG/ML/

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
SANDIMMUNE
SANDOZ PHARMS/SANDOZ 50MG/ML*

SOLUTION; ORAL
SANDIMMUNE
SANDOZ PHARMS/SANDOZ 100MG/ML*

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
CYPROHEPTADINE HCL
AA DURAMED PHARMS 4MG*

DAPSONE (PAGE 3-47)

TABLET; ORAL
>DLT> /AVLOSULFON/
>DLT> /BP/ /AYERST LABS/AMHO/ /25MG/
>DLT> /BP/ /100MG/
DAPSONE
>DLT> /BP/ JACOBUS PHARM 25MG
>DLT> /BP/ 100MG

DESOXIMETASONE (PAGE 3-49)

OINTMENT; TOPICAL
TOPICORT
HOECHST-ROUSSEL 0.25%*

DEXAMETHASONE (PAGE 3-49)

SOLUTION; ORAL
DEXAMETHASONE
ROXANE LABORATORIES 0.5MG/5ML*
DEXAMETHASONE INTENSOL
ROXANE LABORATORIES 0.5MG/0.5ML*

TABLET; ORAL
DECADRON
BP MS&D/MERCK 6MG
DEXAMETHASONE
BP PAR PHARMACEUTICAL 6MG*
BP ROXANE LABORATORIES 6MG*
1MG*

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

INJECTABLE; INJECTION
/HEXADROL PHOSPHATE/
HEXADROL
AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
EQ 20MG PHOSPHATE/ML

SOLUTION/DROPS; OPHTHALMIC
> ADD > DEXAIR
> ADD > AT PHARMAFAIR EQ 0.1% PHOSPHATE*
DEXAMETHASONE SODIUM PHOSPHATE
> ADD > AT BARNES-HIND PHARMS EQ 0.1% PHOSPHATE

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION
/DOPAMINE HCL IN DEXTROSE 5%/
DOPAMINE HCL
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML
AP 5GM/100ML;160MG/100ML
DOPAMINE HCL IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 5GM/100ML;80MG/100ML*
AP 5GM/100ML;160MG/100ML*
5GM/100ML;320MG/100ML*

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION
HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML;4,000 UNITS/100ML*

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION
/DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM/
DIATRIZOATE-60

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

TABLET; ORAL
DIETHYLPROPION HCL
AA CAMALL 25MG*

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION
DIMENHYDRINATE
/AP/ /INTL MEDICATION SYS/ /50MG/ML/

DIPHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL
SK-DIPHENHYDRAMINE
/AA/ SK&F LABORATORIES /25MG/

ELIXIR; ORAL
BELIX
AA HALSEY DRUG 12.5MG/5ML*
> ADD > DIBENIL
> ADD > AA HR CENCI LABS 12.5MG/5ML*
/SK-DIPHENHYDRAMINE/
/AA/ /SK&F LABORATORIES/ /12.5MG/5ML/

DISULFIRAM (PAGE 3-63)

TABLET; ORAL
DISULFIRAM
BX CHELSEA LABORATORIES 250MG*
BX 500MG*
> ADD > BX SIDMAK LABORATORIES 250MG*
> ADD > BX 500MG*

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL
DOXYCYCLINE HYCLATE
AB CHELSEA LABORATORIES EQ 50MG BASE
> ADD > AB HEATHER DRUG EQ 50MG BASE*
> ADD > AB EQ 100MG BASE*
> ADD > AB PAR PHARMACEUTICAL EQ 100MG BASE*
> ADD > AB PUREPAC/KALIPHARMA EQ 50MG BASE*
> ADD > AB EQ 100MG BASE*

INJECTABLE; INJECTION
> ADD > DOXY 100
> ADD > AP LYPHO-MED EQ 100MG BASE/VIAL*
> ADD > DOXY 200
> ADD > AP LYPHO-MED EQ 200MG BASE/VIAL*

DOXYCYCLINE HYCLATE (PAGE 3-64)

INJECTABLE; INJECTION

DOXYCYCLINE

AP		ELKINS-SINN	EQ 100MG BASE/VIAL¤
AP			EQ 200MG BASE/VIAL¤

VIBRAMYCIN

AP		PFIZER LABS/PFIZER	EQ 200MG BASE/VIAL

TABLET; ORAL

DOXYCYCLINE HYCLATE

> ADD >	AB	HEATHER DRUG	EQ 100MG BASE¤

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION

INNOVAR

		/JANSSEN PHARMA/	/2.5MG/ML;0.05MG/ML/
		JANSSEN PHARMA	2.5MG/ML;EQ 0.05MG BASE/ML

ECHOTHIOPHATE IODIDE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPHTHALMIC

> DLT >		/ECHODIDE/	
> DLT >/AT/		/ALCON LABORATORIES/	/0.03%/
> DLT >/AT/			/0.06%/
> DLT >/AT/			/0.125%/
> DLT >/AT/			/0.25%/

PHOSPHOLINE IODIDE

> DLT >/AT/		AYERST LABS/AMHO	0.03%
> DLT >/AT/			0.06%
> DLT >/AT/			0.125%
> DLT >/AT/			0.25%

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION

LIDOCATON

AP		PHARMATON/SZ	0.01MG/ML;2%¤
AP			0.02MG/ML;2%¤

ERGOLOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL

		/HYDERGINE/	
		HYDERGINE LC	

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

AT		E FOUGERA/BYK-GLDN	5MG/GM¤
AT		PHARMADERM/BYK-GLDN	5MG/GM¤

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC

ILOTYCIN

AT		DISTA PRODS/LILLY	5MG/GM

ETOPOSIDE (PAGE 3-74)

INJECTABLE; INJECTION

VEPESID

		BRISTOL LABS/B-M	20MG/ML¤

FENTANYL CITRATE (PAGE 3-75)

INJECTABLE; INJECTION

SUBLIMAZE

		/JANSSEN PHARMA/	/0.05MG/ML/
		JANSSEN PHARMA	EQ 0.05MG BASE/ML

FLUOXYMESTERONE (PAGE 3-77)

TABLET; ORAL

FLUOXYMESTERONE

> ADD >	BP	BOLAR PHARMACEUTICAL	2MG¤
> ADD >	BP		5MG¤
> ADD >	BP		10MG¤
	BP	COLMED LABORATORIES	10MG¤

FUROSEMIDE (PAGE 3-79)

INJECTABLE; INJECTION

FUROSEMIDE

AP		NATCON CHEMICAL	10MG/ML¤

TABLET; ORAL

FUROSEMIDE

AB		ROXANE LABORATORIES	20MG¤
AB			40MG¤
AB		ZENITH LABORATORIES	20MG¤
AB			40MG¤

GENTAMICIN SULFATE (PAGE 3-79)

CREAM; TOPICAL

GENTAFAIR

AT		PHARMAFAIR	EQ 1MG BASE/GM¤

GENTAMICIN SULFATE

AT		NMC LABORATORIES	EQ 1MG BASE/GM¤

GENTAMICIN SULFATE (PAGE 3-79)

INJECTABLE; INJECTION
GENTAMICIN SULFATE

AP	ABBOTT LABORATORIES	EQ 60MG BASE/100ML*
AP		EQ 70MG BASE/100ML*
AP		EQ 80MG BASE/100ML*
AP		EQ 90MG BASE/100ML*
AP		EQ 100MG BASE/100ML*
AP		EQ 1.2MG BASE/ML*
AP		EQ 1.4MG BASE/ML*
AP		EQ 1.6MG BASE/ML*
AP		EQ 1.8MG BASE/ML*
AP		EQ 2MG BASE/ML*
AP		EQ 10MG BASE/ML*
AP		EQ 40MG BASE/ML*
AP	LYPHO-MED	EQ 40MG BASE/ML*

GENTAMICIN SULFATE IN PLASTIC CONTAINER

AP	ABBOTT LABORATORIES	EQ 60MG BASE/100ML*
AP		EQ 70MG BASE/100ML*
AP		EQ 80MG BASE/100ML*
AP		EQ 90MG BASE/100ML*
AP		EQ 100MG BASE/100ML*
AP		EQ 1.2MG BASE/ML*
AP		EQ 1.4MG BASE/ML*
AP		EQ 1.6MG BASE/ML*
AP		EQ 1.8MG BASE/ML*
AP		EQ 2MG BASE/ML*

OINTMENT; TOPICAL
GENTAMICIN SULFATE

> ADD >		
> ADD > AT	THAMES PHARMACAL	EQ 1MG BASE/GM*

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION
/ANTUITRIN S/

/AP/	/PARKE-DAVIS/W-L/	/5,000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL
FULVICIN P/G 165

AB	SCHERING	165MG

FULVICIN P/G 330

AB	SCHERING	330MG

GRISACTIN ULTRA

AB	AYERST LABS/AMHO	165MG*
AB		330MG*

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION
HEPARIN SODIUM

AP	NATCON CHEMICAL	1,000 UNITS/ML*

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL
HOMAPIN-10

/AA/	MISSION PHARMACAL	10MG

/SEDS-TENS SE/

/AA/	/LEMMON/	/10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

TABLET; ORAL
HYDRALAZINE HCL

AA	PAR PHARMACEUTICAL	100MG*
AA	PUREPAC/KALIPHARMA	50MG*

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE (PAGE 3-87)

TABLET; ORAL
/R-HCTZ-H/
RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HCL
RESERPINE, HYDRALAZINE HCL, AND HYDROCHLOROTHIAZIDE

BP	REID-PROVIDENT LABS	25MG;15MG;0.1MG*

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE (PAGE 3-89)

TABLET; ORAL
SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

AB	PUREPAC/KALIPHARMA	25MG;25MG*

HYDROCORTISONE (PAGE 3-90)

CREAM; TOPICAL
ELDECORT

/AT/	ELDER PHARMS	/0.5%/

HYDROCORTISONE

AT	BAY LABORATORIES	1%*
AT		2.5%*

LOTION; TOPICAL
/DELACORT/

/AT/	/MERICON INDUSTRIES/	/0.5%/

GLY-CORT

AT	HERAN PHARMACEUTICAL	1%*

HYDROCORTISONE

AT	MERICON INDUSTRIES	0.5%
/AT/	/TOWNE PAULSEN/	/0.5%/

OINTMENT; TOPICAL
HYDROCORTISOHE

AT	BAY LABORATORIES	1%*
AT		2.5%*

HYDROCORTISONE (PAGE 3-90)

/SOLUTION/DROPS; OPHTHALMIC/
/OPTEF/
/UPJOHN/ /0.2%/

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE (PAGE 3-92)

SOLUTION/DROPS; OTIC
NEO-OTOSOL-HC
AT CARTER-GLOGAU LABS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML*

HYDROCORTISONE ACETATE (PAGE 3-93)

CREAM; TOPICAL
HYDROCORTISONE ACETATE
/AT/ /TOWNE PAULSEN/ /1%/

LOTION; TOPICAL
DRICORT
/AT/ INGRAM PHARM 0.5%
/HYDROCORTISONE ACETATE/
/AT/ /TOWNE PAULSEN/ /0.5%/

/SUSPENSION/DROPS; OPHTHALMIC; OTIC/
/HYDROCORTONE/
/MSD/MERCK/ /2.5%/

HYDROCORTISONE VALERATE (PAGE 3-95)

OINTMENT; TOPICAL
WESTCORT
WESTWOOD PHARMS 0.2%*

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLMED LABORATORIES 50MG;0.125MG*

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG*
AB DANBURY PHARMACAL 10MG*
AB 25MG*
AB 50MG*

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
AB VANGARD LABS/MWM EQ 25MG HCL*
AB EQ 50MG HCL*

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/ANTIPRESS/
/BP/ /LEMMON/ /25MG/
/IMAVATE/
/AB/ /AH ROBINS/ /25MG/
/AB/ /50MG/
IMIPRAMINE HCL
AB PAR PHARMACEUTICAL 10MG*
AB 25MG*
AB 50MG*

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
AN INTL MEDICATION SYS 0.167%
AN ROXANE LABORATORIES 0.167%*
AN TRAVENOL LABS 0.25%*

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5ML*
RIMIFON
AA HOFFMANN-LA ROCHE 50MG/5ML

KANAMYCIN SULFATE (PAGE 3-102)

INJECTABLE; INJECTION
KANAMYCIN SULFATE
AP INTL MEDICATION SYS EQ 500MG BASE/2ML*
AP EQ 1GM BASE/3ML*
KANTREX
/AP/ /BRISTOL LABS/B-M/ /75MG/2ML/
/AP/ /500MG/2ML/
/AP/ /1GM/3ML/
AP BRISTOL LABS/B-M EQ 75MG BASE/2ML
AP EQ 500MG BASE/2ML
AP EQ 1GM BASE/3ML

LIDOCAINE HYDROCHLORIDE (PAGE 3-104)

INJECTABLE; INJECTION
LIDOCATON
AP PHARMATON/SZ 2%¤

METHYLTESTOSTERONE (PAGE 3-121)

TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE
/BP/ /TOWNE PAULSEN/ /10MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRONIDAZOLE
AP ABBOTT LABORATORIES 500MG/100ML¤
METRONIDAZOLE IN PLASTIC CONTAINER
AP ABBOTT LABORATORIES 500MG/100ML¤
METRO I.V. IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 500MG/100ML¤

TABLET; ORAL
METRONIDAZOLE
AB PAR PHARMACEUTICAL 250MG¤
AB 500MG¤

NANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
NANDROLONE DECANOATE
>ADD> AO CARTER-GLOGAU 200MG/ML¤
AO LEMMON 100MG/ML
50MG/ML
AO LYPHO-MED 100MG/ML¤
AO 200MG/ML¤
AO MAURRY BIOLOGICAL 100MG/ML¤

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
AP G POHL-BOSKAMP 5MG/ML¤
1MG/ML¤
TRIDIL
AM CRITICAL CARE/AHS 0.5MG/ML¤

NYSTATIN (PAGE 3-129)

>ADD> POWDER; ORAL
>ADD> NILSTAT
>ADD> LEDERLE LABS/AM CYAN 100%¤

TABLET; ORAL
NYSTATIN
>ADD> AA PAR PHARMACEUTICAL 500,000 UNITS¤

TABLET; VAGINAL
NYSTATIN
AT E FOUGERA/BYK-GLDN 100,000 UNITS¤
AT PHARMADERM/BYK-GLDN 100,000 UNITS¤

>ADD> OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

>ADD> CAPSULE; ORAL
>ADD> TRASICOR
>ADD> CIBA/CIBA-GEIGY 20MG¤
>ADD> 40MG¤
>ADD> 80MG¤
>ADD> 160MG¤

OXTRIPHYLLINE (PAGE 3-131)

>ADD> ELIXIR; ORAL
>ADD> OXTRIPHYLLINE
>ADD> BAY LABORATORIES 100MG/5ML¤

SYRUP; ORAL
CHOLEDYL
>ADD> AA PARKE-DAVIS/W-L 50MG/5ML
>ADD> OXTRIPHYLLINE PEDIATRIC
>ADD> AA BAY LABORATORIES 50MG/5ML¤

TABLET, ENTERIC COATED; ORAL
CHOLEDYL
AB PARKE-DAVIS/W-L 100MG
AB 200MG
OXTRIPHYLLINE
AB BOLAR PHARMACEUTICAL 100MG¤
AB 200MG¤

OXYTETRACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL
/OXLOPAR/
/AB/ /PARKE-DAVIS/W-L/ /EQ 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL
/UTICILLIN VK/
/AA/ /UPJOHN/ /EQ 125MG BASE/5ML/
/AA/ /EQ 250MG BASE/5ML/

PHENDIMETRAZINE TARTRATE (PAGE 3-138)

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
AA FERNDALE LABS 35MG*

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL
ADIPEX-P
AA LEMMON 37.5MG*
DAPEX-37.5
AA FERNDALE LABS 37.5MG*
PHENTERMINE HCL
AA CAMALL 37.5MG*

POTASSIUM CHLORIDE (PAGE 3-143)

INJECTABLE; INJECTION
POTASSIUM CHLORIDE
/AP/ TRAVENOL LABS /1MEQ/ML/
/AP/ /3MEQ/ML/
/AP/ /4MEQ/ML/

PREDNISOLONE (PAGE 3-145)

TABLET; ORAL
PREDNISOLONE
/BX/ /REXALL DRUG/ /5MG/

PREDNISOLONE ACETATE (PAGE 3-146)

INJECTABLE; INJECTION
/FERNISOLONE/
/BP/ /FERNDALE LABS/ /25MG/ML/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC
/HYDELTRASOL/
/AT/ /MSD/MERCK/ /EQ 0.5% PHOSPHATE/
METRETON
/AT/ SCHERING EQ 0.5% PHOSPHATE

PREDNISONE (PAGE 3-147)

TABLET; ORAL
PREDNISONE
BX DURAMED PHARMS 5MG*
BX 10MG*
BX 20MG*

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL
PROCAN
/AB/ PARKE-DAVIS/W-L /250MG/
/AB/ /500MG/

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET; ORAL
PROPANTHELINE BROMIDE
>ADD> AA PAR PHARMACEUTICAL 15MG*

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL
PROPOXYPHENE HCL
AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL
PROPYLTHIOURACIL
/BD/ /MYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL
/PSEUDODINE/
/AA/ /BAY LABORATORIES/ /30MG/5ML;1.25MG/5ML/
/TRIACIN/
/AA/ /NATL PHARM MFG/BARRE/ 30MG/5ML;1.25MG/5ML/
TRIPOSED
HALSEY DRUG 30MG/5ML;1.25MG/5ML*

TABLET; ORAL
/TRIPODRINE/
/AA/ /DANBURY PHARMACAL/ /60MG;2.5MG/
TRIPROLIDINE AND PSEUDOEPHEDRINE
AA BOLAR PHARMACEUTICAL 60MG;2.5MG*
/AA/ /WEST-WARD/ /60MG;2.5MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

TABLET; ORAL
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
AA CHELSEA LABORATORIES 60MG;2.5MG*

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
AB VITARINE/WEST CHEM 300MG*

RESERPINE (PAGE 3-158)

TABLET; ORAL
/RAURINE/
/BP/ /ONEAL JONES&FELDMAN//0.25MG/
/VIO-SERPINE/
/BP/ /ROWELL LABORATORIES//0.1MG/
/BP/ /0.25MG/

SECOBARBITAL SODIUM (PAGE 3-160)

CAPSULE; ORAL
SECOBARBITAL SODIUM
AA LANNETT 50MG
SECONAL SODIUM
AA ELI LILLY 50MG*
AA 100MG*

SELENIUM SULFIDE (PAGE 3-161)

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE
AT BAY LABORATORIES 2.5%*

SILVER SULFADIAZINE (PAGE 3-161)

CREAM; TOPICAL
/SILVER SULFADIAZINE/
SSD

/SITOSTEROL; ALPHA/(PAGE 3-161)

/SUSPENSION; ORAL/
/CYTELLIN/
/ELI LILLY/ /3GM/15ML/

SODIUM CHLORIDE (PAGE 3-162)

INJECTABLE; INJECTION
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER
TRAVENOL LABS 3GM/100ML*
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER
TRAVENOL LABS 5GM/100ML*

SODIUM POLYSTYRENE SULFONATE (PAGE 3-165)

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
AA ROXANE LABORATORIES 15GM/60ML*
SPS
AA CAROLINA MED PRODS 15GM/60ML

SOMATROPIN (PAGE 3-165)

INJECTABLE; INJECTION
ASELLACRIN 2
SERONO LABS 2 IU/VIAL*
/ASELLACRIN/
ASELLACRIN 10

SPIRONOLACTONE (PAGE 3-166)

TABLET; ORAL
SPIRONOLACTONE
AB PUREPAC/KALIPHARMA 25MG*

SULFACETAMIDE SODIUM (PAGE 3-167)

SOLUTION/DROPS; OPHTHALMIC
SODIUM SULFACETAMIDE
> DLT >/AT/ /KETCHUM LABORATORIES/10%/
> DLT >/AT/ /30%/
> ADD > AT OPTOPICS LABS 10%
> ADD > AT 30%
SULFACEL-15
> DLT >/AT/ /STERI-MED/KETCHUM/ /15%/
> ADD > AT OPTOPICS LABS 15%
SULFAIR FORTE
AT PHARMAFAIR 30%

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION
TESTOSTERONE
CARTER-GLOGAU LABS 50MG/ML*

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL

	TETRACYCLINE HCL		
/AB/	/LEMMON/	/250MG/	

TABLET; ORAL

	PANMYCIN		
/AB/	UPJOHN	/250MG/	
	SUMYCIN		
/AB/	ER SQUIBB AND SONS	250MG	

THALLOUS CHLORIDE, TL-201 (PAGE 3-175)

INJECTABLE; INJECTION

	THALLOUS CHLORIDE TL 201		
>ADD>	MEDI-PHYSICS	2MCI/ML	

THEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL

	SOMOPHYLLIN-CRT		
BC	FISONS	100MG	
	THEO-24		
BC	SEARLE/SEARLE PHARMS	100MG¤	
		200MG¤	
		300MG¤	

SOLUTION; ORAL

	THEOLAIR		
AA	RIKER LABS/3M	**80MG/15ML**	
	THEOPHYLLINE		
AA	ROXANE LABORATORIES	**80MG/15ML¤**	

TABLET, CONTROLLED RELEASE; ORAL

	THEOCONTIN		
BC	PURDUE FREDERICK	200MG¤	
	THEO-DUR		
BC	KEY PHARMACEUTICALS	200MG	

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL

	THIORIDAZINE HCL		
AA	CORD LABORATORIES	**30MG/ML¤**	
AA		**100MG/ML¤**	
AA	NATL PHARM MFG/BARRE	**100MG/ML¤**	

TABLET; ORAL

	MELLARIL		
AB	SANDOZ PHARMS/SANDOZ	**100MG**	

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

TABLET; ORAL

	THIORIDAZINE HCL		
AB	BARR LABORATORIES	**10MG¤**	
AB		**15MG¤**	
AB		**25MG¤**	
AB		**50MG¤**	
AB		**100MG¤**	
AB	BOLAR PHARMACEUTICAL	**10MG¤**	
AB		**100MG¤**	
AB	CORD LABORATORIES	**10MG¤**	
AB		**15MG¤**	
AB		**25MG¤**	
AB		**50MG¤**	
AB	DANBURY PHARMACAL	**10MG¤**	
AB		**15MG¤**	
AB		**25MG¤**	
AB		**50MG¤**	
AB	MYLAN PHARMS	**100MG¤**	
>ADD> AB	PAR PHARMACEUTICAL	**10MG¤**	
>ADD> AB		**15MG¤**	
>ADD> AB		**25MG¤**	
>ADD> AB		**50MG¤**	
>ADD> AB		**100MG¤**	
AB	ZENITH LABORATORIES	**100MG¤**	

TIMOLOL MALEATE (PAGE 3-179)

TABLET; ORAL

	BLOCADREN	
	MS&D/MERCK	5MG

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

AEROSOL; INHALATION

>DLT>	/ARISTOCORT/	
>DLT>	/LEDERLE LABS/AM CYAN/0.25MG/INH/	
>ADD>	AZMACORT	
>ADD>	WILLIAM H RORER	0.25MG/INH

CREAM; TOPICAL

	TRIAMCINOLONE ACETONIDE		
AT	BAY LABORATORIES	**0.025%¤**	
AT		**0.1%¤**	
AT		**0.5%¤**	

OINTMENT; TOPICAL

	TRIAMCINOLONE ACETONIDE		
AT	BAY LABORATORIES	**0.025%¤**	
AT		**0.1%¤**	
AT		**0.5%¤**	

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL

	/GUAD-RAMOID/	
/AB/	/ELDER PHARMS/	/500MG/5ML/
	/TRISEM/	
/AB/	/BEECHAM LABS/BEECHAM/	500MG/5ML/
	/TRISUREID/	
/AB/	/REID-PROVIDENT LABS//ᵃ	500MG/5ML/

TABLET; ORAL

	/GUADETTS/	
/AB/	/ELDER PHARMS/	/500MG/
	/TRIPLE SULFA #2/	
/AB/	/ZENITH LABORATORIES//ᵃ	500MG/

TROPICAMIDE (PAGE 3-186)

SOLUTION/DROPS; OPHTHALMIC

	MYDRIAFAIR	
AT	PHARMAFAIR	0.5%ᴺ
AT		1%ᴺ

/TYBAMATE/(PAGE 3-186)

CAPSULE; ORAL

	/TYBATRAN/	
	/AH ROBINS/	/250MG/
		/350MG/

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL

	/SOLVISYN A/	
/AA/	/TOWNE PAULSEN/	/EQ 50,000 UNITS BASE/

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E (PAGE AD2)

INJECTABLE; INJECTION
MVC PLUS

	ASCOT HOSP PHARMS	10MG/ML;0.006MG/ML;0.5 UGM/ML; 1.5MG/ML;20 IU/ML;0.04MG/ML; 4MG/ML;0.4MG/ML;0.36MG/ML; 0.3MG/ML;330 IU/ML;1 IU/ML

> DLT > /BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE/
> DLT > /PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

> DLT > /ELIXIR; ORAL/
> DLT > /ELIXIR; DIMETAPP/
> DLT > /AH ROBINS/ /4MG/5ML;5MG/5ML;5MG/5ML/

> DLT > /TABLET; CONTROLLED RELEASE; ORAL/
> DLT > /DIMETAPP/
> DLT > /AH ROBINS/ /12MG;15MG;15MG/

/CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE; ISOPROPAMIDE/ /IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE/ (PAGE AD3)

/CAPSULE; CONTROLLED RELEASE; ORAL/
/TUSS-ORNADE/
/SKAF LABORATORIES/ /20MG;8MG;2.5MG;50MG/

/SOLUTION; ORAL/
/TUSS-ORNADE/
/SKAF LABORATORIES/ /5MG/5ML;2MG/5ML;0.75/5ML;15MG/5ML/

DICYCLOMINE HYDROCHLORIDE (PAGE AD3)

SYRUP; ORAL
> ADD > BAYCYCLOMINE
> ADD > BAY LABORATORIES 10MG/5ML

DIPYRIDAMOLE (PAGE AD4)

TABLET; ORAL
DIPYRIDAMOLE

	ASCOT HOSP PHARMS	50MG
> ADD >	DURAMED PHARMS	25MG
> ADD >		50MG
> ADD >		75MG
	HALSEY DRUG	50MG
	SUPERPHARM	50MG

/METHANDROSTENOLONE/ (PAGE AD6)

/TABLET; ORAL/
/METHANDROSTENOLONE/
/PAR PHARMACEUTICAL/ /2.5MG/
/5MG/

CURRENT STATUS - INEFFECTIVE

/CARBRITAL/ /PARKE-DAVIS/W-L/
/CARBROMAL; PENTOBARBITAL SODIUM/

/CLISTIN RA/ /MCNEIL PHARM/
/CARBINOXAMINE MALEATE/

>_ADD_> DIMETAPP AH ROBINS
>_ADD_> BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
>_ADD_> PHENYLPROPANOLAMINE HYDROCHLORIDE

>_ADD_> ELIXIR DIMETAPP AH ROBINS
>_ADD_> BROMPHENIRAMINE MALEATE; PHENYLEPHRINE HYDROCHLORIDE;
>_ADD_> PHENYLPROPANOLAMINE HYDROCHLORIDE

/FORHISTAL/ /CIBA/CIBA-GEIGY/
/DIMETHINDENE MALEATE/

METHANDROSTENOLONE PAR PHARMACEUTICAL
METHANDROSTENOLONE

TUSS-ORNADE SK&F LABORATORIES
CARAMIPHEN EDISYLATE; CHLORPHENIRAMINE MALEATE;
ISOPROPAMIDE IODIDE; PHENYLPROPANOLAMINE HYDROCHLORIDE

☆ U.S. GOVERNMENT PRINTING OFFICE: 1984- 421-927:206